Evidence map›Paper›PMID 37274287›Full record

ReviewFrontiers in oncology2023

The multidisciplinary approach to eosinophilia.

Gunhild Nynke Thomsen, Mette Niemann Christoffersen, Hanne Merete Lindegaard, Jesper Rømhild Davidsen, Gitte Nyvang Hartmeyer, Kristian Assing, Charlotte G Mortz, Raquel Martin-Iguacel, Michael Boe Møller, Anette Drøhse Kjeldsen and 8 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. The Clinical Burden of Hypereosinophilic Syndrome in a Large United States Cohort.The journal of allergy and clinical immunology. In practice · 2026
    Article
  7. Prediction model to identify patients with hypereosinophilic syndrome using real-world data.The journal of allergy and clinical immunology. Global · 2026
    Article
  8. Hypereosinophilia: clinical and therapeutic approach in 2025.Current opinion in allergy and clinical immunology · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Gunhild Nynke ThomsenDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Mette Niemann ChristoffersenDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Hanne Merete LindegaardDepartment of Rheumatology, Odense University Hospital, Denmark; Research Unit for Rheumatology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.
Jesper Rømhild DavidsenDepartment of Respiratory Medicine, Odense University Hospital, Denmark; Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Gitte Nyvang HartmeyerDepartment of Clinical Microbiology, Odense University Hospital, Odense, Denmark.
Kristian AssingDepartment of Clinical Immunology, Odense University Hospital, Odense, Denmark.
Charlotte G MortzDepartment of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Denmark; University of Southern Denmark, Odense, Denmark.
Raquel Martin-IguacelDepartment of Infectious Diseases , Odense University Hospital, Odense, Denmark.
Michael Boe MøllerDepartment of Pathology, Odense University Hospital, Odense, Denmark.
Anette Drøhse KjeldsenDepartment of ORL- Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.
Troels HavelundDepartment of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.
Daniel El FassiDepartment of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Sigurd Broesby-OlsenDepartment of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Denmark; University of Southern Denmark, Odense, Denmark.
Michael MaiborgDepartment of Cardiology, Odense University Hospital, Odense, Denmark.
Sofie Lock JohanssonDepartment of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
Christen Lykkegaard AndersenDepartment of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Hanne VestergaardDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Ole Weis BjerrumDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Odense University Hospital · DKUniversity of Southern Denmark · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic granulocytes are normally present in low numbers in the bloodstream. Patients with an increased number of eosinophilic granulocytes in the differential count (eosinophilia) are common and can pose a clinical challenge because conditions with eosinophilia occur in all medical specialties. The diagnostic approach must be guided by a thorough medical history, supported by specific tests to guide individualized treatment. Neoplastic (primary) eosinophilia is identified by one of several unique acquired genetic causes. In contrast, reactive (secondary) eosinophilia is associated with a cytokine stimulus in a specific disease, while idiopathic eosinophilia is a diagnosis by exclusion. Rational treatment is disease-directed in secondary cases and has paved the way for targeted treatment against the driver in primary eosinophilia, whereas idiopathic cases are treated as needed by principles in eosinophilia originating from clonal drivers. The vast majority of patients are diagnosed with secondary eosinophilia and are managed by the relevant specialty-e.g., rheumatology, allergy, dermatology, gastroenterology, pulmonary medicine, hematology, or infectious disease. The overlap in symptoms and the risk of irreversible organ involvement in eosinophilia, irrespective of the cause, warrants that patients without a diagnostic clarification or who do not respond to adequate treatment should be referred to a multidisciplinary function anchored in a hematology department for evaluation. This review presents the pathophysiology, manifestations, differential diagnosis, diagnostic workup, and management of (adult) patients with eosinophilia. The purpose is to place eosinophilia in a clinical context, and therefore justify and inspire the establishment of a multidisciplinary team of experts from diagnostic and clinical specialties at the regional level to support the second opinion. The target patient population requires highly specialized laboratory analysis and therapy and occasionally has severe eosinophil-induced organ dysfunction. An added value of a centralized, clinical function is to serve as a platform for education and research to further improve the management of patients with eosinophilia. Primary and idiopathic eosinophilia are key topics in the review, which also address current research and discusses outstanding issues in the field.

Indexed as

clinicaldiagnosiseosinophiliamultidisciplinaryreviewtreatmenttrial

Identifiers

PMID37274287
PMCPMC10232806
OpenAlexW4377023780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.